Alnylam Pharmaceuticals
ALNY
#639
Rank
$39.33 B
Marketcap
$294.59
Share price
3.42%
Change (1 day)
9.03%
Change (1 year)
Alnylam Pharmaceuticals Inc. is a biopharmaceutical company focused on the R&D and commercialization of RNA interference (RNAi) therapeutics for genetically defined diseases.

EPS for Alnylam Pharmaceuticals (ALNY)

EPS in 2026 (TTM): $3.79

According to Alnylam Pharmaceuticals 's latest financial reports the company's current EPS (TTM) is $3.79. In 2025 the company made an earnings per share (EPS) of $1.80.

EPS history for Alnylam Pharmaceuticals from 2012 to 2026

Annual EPS

Year EPS Change
2026 (TTM)$3.79110.56%
2025$1.80
2023-$3.53-62%
2022-$9.2929.03%
2021-$7.20-3.36%
2020-$7.45-8.48%
2019-$8.147.67%
2018-$7.5639.74%
2017-$5.4112.94%
2016-$4.7938.84%
2015-$3.45-32.88%
2014-$5.14259.44%
2013-$1.43-31.25%
2012-$2.08

EPS for similar companies or competitors

Company EPS EPS differencediff. Country
Novartis
NVS
$7.02 85.22%๐Ÿ‡จ๐Ÿ‡ญ Switzerland
Sanofi
SNY
$2.56-32.46%๐Ÿ‡ซ๐Ÿ‡ท France
Regeneron Pharmaceuticals
REGN
$42.53 1,022.16%๐Ÿ‡บ๐Ÿ‡ธ USA
Sarepta Therapeutics
SRPT
-$8.32-319.53%๐Ÿ‡บ๐Ÿ‡ธ USA
Regulus Therapeutics
RGLS
-$0.73-119.26%๐Ÿ‡บ๐Ÿ‡ธ USA
OPKO Health
OPK
-$0.24-106.33%๐Ÿ‡บ๐Ÿ‡ธ USA
Teva Pharmaceutical Industries
TEVA
$1.37-63.85%๐Ÿ‡ฎ๐Ÿ‡ฑ Israel
Arrowhead Pharmaceuticals
ARWR
$0.35-90.77%๐Ÿ‡บ๐Ÿ‡ธ USA